IL17A
Interleukin-17A
As of the edition of 20 October 2026, IL17A (interleukin-17A, UniProt Q16552) has 18 drugs tested at it and 19 companies on the list, 7 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16552
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 44
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Immune system; Infections; Eye; Heart and blood vessels; Lungs and airways; Nervous system
- Registered trials of its drugs
- 368
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 4 |
| Went quiet | 6 |
| Stopped | 4 |
| Status not established | 1 |
| Total | 18 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Secukinumab | Marketed | Phase 4 | Ends 2027 |
| Ixekizumab | Marketed | Phase 4 | Ends 2028 |
| Bimekizumab | Marketed | Phase 4 | Ends 2035 |
| Vunakizumab | Active | Phase 4 | none listed |
| M-1095 | Active | Phase 3 | none listed |
| Izokibep | Stopped | Phase 3 | none listed |
| Roconkibart | Stopped | Phase 3 | none listed |
| CJM-112 | Went quiet | Phase 2 | none listed |
| Tibulizumab | Active | Phase 3 | none listed |
| BCD-085 | Stopped | Phase 3 | none listed |
| Remtolumab | Went quiet | Phase 2 | none listed |
| Cnto 6785 | Went quiet | Phase 2 | none listed |
12 of 18 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Route B | 3 |
| Engaged | 8 |
| Undetermined | 1 |
| Total on the list | 19 |
The other 16 companies at IL17A
In the product19 companies in all; 16 are not named here, and no score is.
See the 19 companies at IL17A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.